Jeffrey D Stanaway1, Abraham D Flaxman2, Mohsen Naghavi2, Christina Fitzmaurice3, Theo Vos2, Ibrahim Abubakar4, Laith J Abu-Raddad5, Reza Assadi6, Neeraj Bhala7, Benjamin Cowie8, Mohammad H Forouzanfour2, Justina Groeger9, Khayriyyah Mohd Hanafiah10, Kathryn H Jacobsen11, Spencer L James12, Jennifer MacLachlan8, Reza Malekzadeh13, Natasha K Martin14, Ali A Mokdad15, Ali H Mokdad2, Christopher J L Murray2, Dietrich Plass16, Saleem Rana17, David B Rein18, Jan Hendrik Richardus19, Juan Sanabria20, Mete Saylan21, Saeid Shahraz22, Samuel So23, Vasiliy V Vlassov24, Elisabete Weiderpass25, Steven T Wiersma26, Mustafa Younis27, Chuanhua Yu28, Maysaa El Sayed Zaki29, Graham S Cooke30. 1. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: stanaway@uw.edu. 2. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. 3. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA. 4. Institute for Global Health, University College London, London, UK. 5. Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar. 6. Mashhad University of Medical Sciences, Mashhad, Iran. 7. Queen Elizabeth Hospital Birmingham, Birmingham, UK; University of Otago Medical School, Wellington, New Zealand. 8. WHO Collaborating Centre for Viral Hepatitis, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia; Doherty Institute, University of Melbourne, Melbourne, VIC, Australia. 9. Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. 10. Centre for Biomedical Research, Burnet Institute, Melbourne, VIC, Australia; School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia. 11. Department of Global and Community Health, George Mason University, Fairfax, VA, USA. 12. Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA. 13. Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 14. Division of Global Public Health, University of California San Diego, San Diego, CA, USA; School of Social and Community Medicine, University of Bristol, Bristol, UK. 15. Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. 16. Section Exposure Assessment and Environmental Health Indicators, Federal Environmental Agency, Berlin, Germany. 17. Contech School of Public Health, Lahore, Pakistan; Contech International Health Consultants, Lahore, Pakistan. 18. NORC at the University of Chicago, Chicago, IL, USA. 19. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 20. Case Western Reserve University, Cleveland, OH, USA; Cancer Treatment Centers of America, Rosalind Franklin University Chicago Medical School, North Chicago, IL, USA. 21. Bayer AG Turkey, Fatih Sultan Mehmet Mah Balkan Cad, Istanbul, Turkey. 22. Tufts Medical Center, Boston, MA, USA. 23. Asian Liver Center, Stanford University School of Medicine, Palo Alto, CA, USA. 24. National Research University Higher School of Economics, Moscow, Russia. 25. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; Department of Research, Cancer Registry of Norway, Oslo, Norway; Department of Community Medicine, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, Tromsø, Norway; Genetic Epidemiology Group, Folkhälsan Research Center, University of Helsinki, Helsinki, Finland. 26. US Centers for Disease Control and Prevention, Kampala, Uganda. 27. Jackson State University, Jackson, MS, USA. 28. Department of Epidemiology and Biostatistics, School of Public Health, and Global Health Institute, Wuhan University, Wuhan, Hubei, China. 29. Faculty of Medicine, Mansoura University, Mansoura, Egypt. 30. Division of Infectious Diseases, Imperial College, London, UK. Electronic address: g.cooke@imperial.ac.uk.
Abstract
BACKGROUND: With recent improvements in vaccines and treatments against viral hepatitis, an improved understanding of the burden of viral hepatitis is needed to inform global intervention strategies. We used data from the Global Burden of Disease (GBD) Study to estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2013. METHODS: We estimated mortality using natural history models for acute hepatitis infections and GBD's cause-of-death ensemble model for cirrhosis and liver cancer. We used meta-regression to estimate total cirrhosis and total liver cancer prevalence, as well as the proportion of cirrhosis and liver cancer attributable to each cause. We then estimated cause-specific prevalence as the product of the total prevalence and the proportion attributable to a specific cause. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost (YLLs) and years lived with disability (YLDs). FINDINGS: Between 1990 and 2013, global viral hepatitis deaths increased from 0·89 million (95% uncertainty interval [UI] 0·86-0·94) to 1·45 million (1·38-1·54); YLLs from 31·0 million (29·6-32·6) to 41·6 million (39·1-44·7); YLDs from 0·65 million (0·45-0·89) to 0·87 million (0·61-1·18); and DALYs from 31·7 million (30·2-33·3) to 42·5 million (39·9-45·6). In 2013, viral hepatitis was the seventh (95% UI seventh to eighth) leading cause of death worldwide, compared with tenth (tenth to 12th) in 1990. INTERPRETATION: Viral hepatitis is a leading cause of death and disability worldwide. Unlike most communicable diseases, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013. The enormous health loss attributable to viral hepatitis, and the availability of effective vaccines and treatments, suggests an important opportunity to improve public health. FUNDING: Bill & Melinda Gates Foundation.
BACKGROUND: With recent improvements in vaccines and treatments against viral hepatitis, an improved understanding of the burden of viral hepatitis is needed to inform global intervention strategies. We used data from the Global Burden of Disease (GBD) Study to estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2013. METHODS: We estimated mortality using natural history models for acute hepatitis infections and GBD's cause-of-death ensemble model for cirrhosis and liver cancer. We used meta-regression to estimate total cirrhosis and total liver cancer prevalence, as well as the proportion of cirrhosis and liver cancer attributable to each cause. We then estimated cause-specific prevalence as the product of the total prevalence and the proportion attributable to a specific cause. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost (YLLs) and years lived with disability (YLDs). FINDINGS: Between 1990 and 2013, global viral hepatitis deaths increased from 0·89 million (95% uncertainty interval [UI] 0·86-0·94) to 1·45 million (1·38-1·54); YLLs from 31·0 million (29·6-32·6) to 41·6 million (39·1-44·7); YLDs from 0·65 million (0·45-0·89) to 0·87 million (0·61-1·18); and DALYs from 31·7 million (30·2-33·3) to 42·5 million (39·9-45·6). In 2013, viral hepatitis was the seventh (95% UI seventh to eighth) leading cause of death worldwide, compared with tenth (tenth to 12th) in 1990. INTERPRETATION: Viral hepatitis is a leading cause of death and disability worldwide. Unlike most communicable diseases, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013. The enormous health loss attributable to viral hepatitis, and the availability of effective vaccines and treatments, suggests an important opportunity to improve public health. FUNDING: Bill & Melinda Gates Foundation.
Authors: David B Rein; Katherine A Hicks; Kathleen E Wirth; Kaafee Billah; Lyn Finelli; Anthony E Fiore; Thomas J Hoerger; Beth P Bell; Gregory L Armstrong Journal: Pediatrics Date: 2007-01 Impact factor: 7.124
Authors: Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein Journal: N Engl J Med Date: 2013-01-03 Impact factor: 91.245
Authors: Juanita A Haagsma; Charline Maertens de Noordhout; Suzanne Polinder; Theo Vos; Arie H Havelaar; Alessandro Cassini; Brecht Devleesschauwer; Mirjam E Kretzschmar; Niko Speybroeck; Joshua A Salomon Journal: Popul Health Metr Date: 2015-04-03
Authors: Jeanne Heil; Christian J P A Hoebe; Jochen W L Cals; Henriëtte L G Ter Waarbeek; Inge H M van Loo; Nicole H T M Dukers-Muijrers Journal: Ann Fam Med Date: 2018-01 Impact factor: 5.166
Authors: Rebecca Rose; Christopher Rodriguez; James Jarad Dollar; Susanna L Lamers; Guido Massaccesi; William Osburn; Stuart C Ray; David L Thomas; Andrea L Cox; Oliver Laeyendecker Journal: Infect Genet Evol Date: 2019-02-22 Impact factor: 3.342
Authors: Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice Journal: Int J Drug Policy Date: 2018-04-12
Authors: Laura Rivino; Nina Le Bert; Upkar S Gill; Kamini Kunasegaran; Yang Cheng; Damien Zm Tan; Etienne Becht; Navjyot K Hansi; Graham R Foster; Tung-Hung Su; Tai-Chung Tseng; Seng Gee Lim; Jia-Horng Kao; Evan W Newell; Patrick Tf Kennedy; Antonio Bertoletti Journal: J Clin Invest Date: 2018-01-08 Impact factor: 14.808